<DOC>
	<DOCNO>NCT00002001</DOCNO>
	<brief_summary>To evaluate virologic effect combine administration zidovudine ddI ddC . To evaluate immunologic effect zidovudine ddI ddC . To evaluate combined administration zidovudine ddI ddC clinical efficacy . To evaluate safety tolerance coadministration zidovudine ddI ddC .</brief_summary>
	<brief_title>The Antiviral Efficacy Concurrent Zidovudine 2',3'-Dideoxyinosine 2',3'-Dideoxycytidine Patients With Human Immunodeficiency Virus Disease</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Patients PCP may randomize study medication contact sponsor follow minimum 7day course therapy result stabilization disease . Patients stabilized disease must fever &lt; 39 C least 48 hour , p02 ( room air ) &gt; = 60 mm A/A gradient &lt; = 30 mm . Prophylaxis PCP . Patients must follow : HIV1 seropositive federally license ELISA . Willingness give inform consent . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Any immediately lifethreatening infection medical condition present time study entry . Any active opportunistic infection require chronic therapy agent list exclusion concurrent medication section . Neoplasms basal cell carcinoma situ carcinoma cervix . Kaposi 's sarcoma visceral involvement require systemic cytotoxic chemotherapy . AIDS dementia complex , &gt; = Stage 2 . History zidovudine induce toxicity . Prior history acute pancreatitis past two year chronic pancreatitis . Grade 2 neuropathy . Intractable diarrhea . History seizure within past six month current requirement anticonvulsant . Past current heart disease . Fever &gt; 39 C entry . Concurrent Medication : Current requirement anticonvulsant . Excluded : It intend patient develop new opportunistic infection course study continue study participation , unless require therapy associate significant neurologic hematologic toxicity , case study medication may temporarily discontinue . Ganciclovir . Chloramphenicol . Cisplatinum . Iodoquinol . Systemic Pentamidine . Disulfiram . Ethionamide . Glutethimide . Gold . Hydralazine . Metronidazole . Sodium Cyanate . Thalidomide . Vincristine . Allopurinol . Probenecid . Concurrent Treatment : Excluded : Radiation therapy . ( exception electron beam therapy area &lt; 100cm/m2 . ) Patients follow exclude : Any immediately lifethreatening infection medical condition present time study entry . Any active opportunistic infection require chronic therapy agent list exclusion concurrent medication section . Active alcohol drug abuse , sufficient investigator 's opinion prevent compliance study therapy . Neoplasms basal cell carcinoma situ carcinoma cervix . Kaposi 's syndrome visceral involvement require systemic cytotoxic chemotherapy . AIDS dementia complex , &gt; = Stage 2 . History zidovudine induce toxicity . Any experimental therapy within 30 day . Prior history acute pancreatitis past two year chronic pancreatitis . Grade 2 neuropathy . Intractable diarrhea . History seizure within past six month current requirement anticonvulsant . History past current heart disease . Fever &gt; 39 C entry . Prior Medication : Excluded : Any antiHIV therapy ( zidovudine ) , biologic response modifier , pharmacologic dos corticosteroid within eight week entry ( except management severe PCP , case duration exceed 21 day ) . Zidovudine therapy great four week prior discontinuation due drug toxicity . Prior therapy ddI , ddC , D4T , interferon . Any experimental therapy within 30 day . Therapy within 30 day neurotoxic drug . Prior Treatment : Excluded : Radiation therapy within two week entry likely require radiation therapy ( exception electron beam therapy area &lt; 100cm/m2 ) . Active alcohol drug abuse , sufficient investigator 's opinion , prevent compliance study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 1991</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>